Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Piramal Pharma Limited ( (IN:PPLPHARMA) ) is now available.
Piramal Pharma Limited has been assigned an ESG Rating of ’61’ for the fiscal year 2023-24 by NSE Sustainability Ratings and Analytics Limited. This rating, which the company did not solicit, reflects the company’s performance in environmental, social, and governance aspects based on publicly available data. The rating could impact the company’s reputation and stakeholder perceptions regarding its commitment to sustainable practices.
More about Piramal Pharma Limited
Piramal Pharma Limited operates in the pharmaceutical industry, providing a range of pharmaceutical products and services. The company is focused on delivering high-quality healthcare solutions and has a significant presence in the market.
Average Trading Volume: 210,129
Current Market Cap: 267.6B INR
See more insights into PPLPHARMA stock on TipRanks’ Stock Analysis page.